scholarly journals Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling

2020 ◽  
Author(s):  
Gregory S. Calip ◽  
John Kidd ◽  
Ryan Bernhisel ◽  
Hannah C. Cox ◽  
Jennifer Saam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Cancer Risk Counseling ◽  
History Of ◽  
Breast Cancer In Men

scholarly journals Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy

Breast Care ◽  
2019 ◽  
Vol 15 (1) ◽  
pp. 14-21 ◽  
Author(s):  
Francesca Pellini ◽  
Eleonora Granuzzo ◽  
Silvia Urbani ◽  
Sara Mirandola ◽  
Marina Caldana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
High Risk ◽  
Male Breast Cancer ◽  
Brca2 Mutation ◽  
Positive Family History ◽  
Male Breast ◽  
Mutation Carriers ◽  
History Of ◽  
Clinical Records

Background: Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and BRCA1/2 mutations, which indicate a relevant genetic role. Methods: In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Participants’ electronic clinical records were reviewed. Patients’ data reported age at diagnosis, tumor characteristics, therapeutic management, and BRCA1/2 status as well as a family history of breast, ovarian, or prostate cancer (PCa) in first-degree relatives. Results: We analyzed 69 MBC patients. Median age was 64 years. The majority of tumors diagnosed were of an early TNM stage. The most frequent histological subtype was invasive ductal carcinoma (76.7%). Hormone receptors were positive in >90% of MBC cases. Nearly all patients underwent modified radical mastectomy or total mastectomy. Adjuvant endocrine therapy was delivered in 59.4%. Among MBC-affected patients, we recorded a high percentage of a positive family history of BC. Mutational analysis for the BRCA1/2 genes was performed in 17 MBC patients; 11.8% were carriers of BRCA2 pathogenic mutations. Among 26 healthy high-risk subjects included in this case series, 4 were BRCA1 mutation carriers and 9 were BRCA2 mutation carriers. Discussion: We evaluated the distribution of clinicopathological characteristics in MBC subjects and assessed the frequency of mutations in the BRCA genes in affected patients and healthy high-risk subjects, with the aim of proposing a surveillance program for BC and PCa.

Family history of breast cancer in non-BRCA male breast cancer: A case-control study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13032-e13032
Author(s):  
Gregory Sampang Calip ◽  
Katherine Rebecca Exten ◽  
Garth H Rauscher ◽  
Krystal Brown ◽  
Ryan Bernhisel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Case Control Study ◽  
Brca Mutation ◽  
Case Control ◽  
Cancer Risk Counseling ◽  
Mmr Genes ◽  
History Of ◽  
Control Study

e13032 Background: Approximately 85% of male breast cancer (MBC) patients test negative for a BRCA mutation, and the role of genetic predisposition is unclear. Cancer risk counseling for unaffected relatives of BRCA-negative MBC patients relies on accurate cancer risk estimates, but there is limited data on the risk of breast cancer (BC) for relatives of these men. We characterized the association between MBC and family history of BC in patients who test negative for BRCA mutations in order to facilitate cancer risk counseling and to explore the possibility of unidentified MBC susceptibility alleles. Methods: We performed a case-control study of patients who had full length sequencing and large-rearrangement analysis for germline mutations in BRCA1/2 or the mismatch repair (MMR) genes at a commercial laboratory from 2006-2012. Cases were MBC patients who tested negative for a BRCA1/2 mutation (n = 3,647); controls were male colon cancer patients who tested negative for mutations in MMR genes (n = 4,269). Information on family history of BC was ascertained from test request forms completed by the ordering healthcare provider at the time of testing. Unconditional multivariable logistic regression models estimated odds ratios (OR) and 95% confidence intervals (CI) for associations between family history of BC in first- (FDR) and second-degree relatives (SDR) and MBC with adjustment for potential confounders (age, ethnicity, year of testing). Results: Compared to controls, MBC cases had higher odds of BC in a FDR or SDR (OR = 4.7; 95% CI 4.1, 5.3). Associations were strongest for family history of BC in 1 female FDR (OR = 3.9; 95% CI: 3.3, 4.6), ≥2 female FDR (OR = 7.5; 95% CI 5.0, 11.4), BC in a FDR < 45 years old (for cases diagnosed < 45, OR = 6.9; 95% CI 3.9, 12.4), a male FDR or SDR with BC (OR = 17.9; 95% CI 7.6, 42.1), and both a male and female FDR or SDR with BC (OR = 15.7; 95%CI 4.4, 55.3). Conclusions: MBC patients who test negative for a BRCA mutation have significantly higher odds of reporting family members affected by breast cancer, particularly with affected FDR < 45 years old, multiple affected relatives, and male relatives with BC. This data can guide risk counseling in MBC families, and suggests the existence of unidentified MBC susceptibility alleles.

Does a Family History of Male Breast Cancer Influence Risk Perception and Use of Genetic Testing?

2010 ◽  
Vol 76 (8) ◽  
pp. 879-882
Author(s):  
Suzanne C. Schiffman ◽  
Anees B. Chagpar
Keyword(s):  
Breast Cancer ◽  
Genetic Testing ◽  
Risk Perception ◽  
Family History ◽  
Male Breast Cancer ◽  
Population Based ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Degree Relative ◽  
History Of

We sought to determine differences in risk perception and use of genetic testing in these individuals compared with those with a family history of female breast cancer (FHxFBC) in a population-based cohort. Data from the 2005 National Health Interview Survey were used to assess risk perception and use of genetic counseling in individuals with a family history of male breast cancer (FHxMBC) versus those with a FHxFBC. Of the 2429 individuals with a first-degree relative with breast cancer surveyed, 21 (0.7%) had a FHxMBC, whereas 2408 (99.3%) had a FHxFBC. Women who had a FHxMBC perceived themselves as being at higher risk for developing breast cancer than those with a FHxFBC (61.5 vs 46.5%, P = 0.011). Fewer individuals with a FHxMBC had heard about genetic testing than those with a FHxFBC (38.4 vs 50.8%, P = 0.322). Of these, none of the individuals with a FHxMBC discussed this with their physician (vs 13% of individuals with a FHxFBC, P = 0.004) and none underwent genetic testing (vs 3% of individuals with a FHxFBC, P = 0.009). Women with a FHxMBC perceive this as being associated with increased cancer risk, but few discuss this with their physicians. Physicians should be proactive in discussing risk with these patients.

The effect of family history on adherence to breast cancer screening guidelines.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1571-1571
Author(s):  
Lauren Marie Hibler ◽  
Anees B. Chagpar
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Male Breast Cancer ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Screening Guidelines ◽  
The Past ◽  
Female Breast ◽  
Income Insurance ◽  
History Of

1571 Background: A family history of breast cancer increases the risk of developing this disease. We sought to determine the effect of a family history of a first degree relative with breast cancer (FDFHx) on adherence to mammography (MMG) and clinical breast examination (CBE) guidelines. Methods: The National Health Interview Survey (NHIS), conducted annually by the Centers for Disease Control, is designed to be representative of the US population. The 2010 NHIS data was used to evaluate the effect of FDFHx on the likelihood that women aged ≥ 30 had MMG and/or CBE within the past year. Results: Of the 12,320 women aged ≥ 30, 1276 (10.7%) had a FDFHx; 1263 (99.0%) of female breast cancer and 13 (1.0%) of male breast cancer. Overall, 4573 (38.4%) of women reported having had MMG within the past year; 5377 (46.3%) had CBE within the past year. FDFHx was associated with use of MMG and CBE within the past year (58.0% vs. 36.0%, p<0.001, and 57.5% vs. 45.0%, p<0.001, respectively). Women with a FDFHx of male breast cancer were no more likely to have MMG (72.5% vs. 57.9%, p=0.313) nor CBE (66.8% vs. 57.4%, p=0.518) within the past year than those with a FDFHx of female breast cancer. On multivariate analysis controlling for age, race, personal history of breast cancer (PHx), income, insurance, education and region, FDFHx was associated with a higher likelihood of having MMG (OR=1.75; 95% CI: 1.48-2.06, p<0.001) and CBE (OR=1.48; 95% CI: 1.26-1.74, p<0.001) within the past year. Region was not associated with adherence to either MMG or CBE screening guidelines. Conclusions: FDFHx, along with age, race, PHx, income, insurance, and education, is an independent predictor of adherence to screening MMG and CBE guidelines. Still, only 58% of women with a FDFHx had MMG and CBE in the past year. Further efforts are warranted to improve screening in this population at increased risk. [Table: see text]

scholarly journals Evaluating the Effect of Health Education Intervention on the Health Beliefs and Behaviors of First-Degree Female Relatives of Breast Cancer Patients

2021 ◽  
Author(s):  
Sule Olgun ◽  
Berna Dizer
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Health Education ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Health Beliefs ◽  
Breast Cancer Patients ◽  
History Of ◽  
And Behaviors

Abstract Background Breast cancer risk increases by 80% in the presence of BRCA1 and BRCA2 gene mutations in the same family. In particular, a woman whose sister or mother has breast cancer has a 2- to 5-fold higher risk of developing breast cancer compared with other women. For this reason, recommendations should have been made regarding breast cancer prevention and/or early detection for women with first-degree family history of breast cancer. Aim The aim of this study was to evaluate the effect of health education, which was provided to first-degree female relatives of breast cancer patients, on their health beliefs and behaviors. Study Design and Methods The study sample included 50 women with a first-degree relative being treated for breast cancer in the chemotherapy and radiotherapy unit of a university hospital. A one-group pretest-posttest design was used. The pretest consisted of the health belief model scale and a questionnaire regarding the women’s sociodemographic information and breast cancer screening behaviors. After the pretest, the patients received health education regarding breast cancer risk factors and screening methods. The posttest was conducted 3 weeks after the education using the same assessment tools. Results After education, there were statistically significant increases in rates of practicing breast self-examination, having clinical breast examinations, and undergoing breast ultrasound/mammography compared with pretest results. Conclusions Health workers should possess knowledge and experience about breast cancer which will enable them to effectively undertake an educational role, especially for high-risk groups such as women with first-degree family history of breast cancer.

Male Breast Cancer

2017 ◽  
Author(s):  
Kimberly S. Stone ◽  
Irene L Wapnir
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Genetic Predisposition ◽  
Breast Conserving Surgery ◽  
Lymph Node Biopsy ◽  
Male Breast ◽  
Therapeutic Approaches ◽  
Breast Masses ◽  
Key Words Breast ◽  
Breast Cancer In Men

This is a contemporary review of risk factors and genetic predisposition associated with breast cancer in men. The workup and evaluation of breast masses and surgical management of cancer in this population are detailed. In addition, systemic therapies for the treatment of breast cancer in men are reviewed and compared with the therapeutic approaches used for women.    This reviews contains 5 figures, 2 tables and 50 references.  Key words: breast-conserving surgery, chemotherapy, endocrine therapy, genetic predisposition testing, genomic profiling, lymphadenectomy, male breast cancer, mastectomy, radiotherapy, sentinel lymph node biopsy

scholarly journals First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zheng-Ju Ren ◽  
De-Hong Cao ◽  
Qin Zhang ◽  
Peng-Wei Ren ◽  
Liang-Ren Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Family History ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
History Of

Management of Male Breast Cancer: ASCO Guideline

2020 ◽  
Vol 38 (16) ◽  
pp. 1849-1863 ◽  
Author(s):  
Michael J. Hassett ◽  
Mark R. Somerfield ◽  
Elisha R. Baker ◽  
Fatima Cardoso ◽  
Kari J. Kansal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Male Breast Cancer ◽  
Early Stage ◽  
Metastatic Cancer ◽  
Male Breast ◽  
Eligibility Criteria ◽  
Early Stage Disease ◽  
First Line Therapy ◽  
History Of

PURPOSE To develop recommendations concerning the management of male breast cancer. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations. RECOMMENDATIONS Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of therapy. Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy regardless of genetic predisposition; contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. Breast magnetic resonance imaging is not recommended routinely. Genetic counseling and germline genetic testing of cancer predisposition genes should be offered to all men with breast cancer.

Sign in / Sign up

Export Citation Format

Share Document